https://orcid.org/0000-0003-2287-4430
References
- Chovatiya R, Medzhitov R. Stress, inflammation, and defense of homeostasis. Mol Cell. 2014;54(2):281–288.
- Chen L, Deng H, Cui H, et al. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget. 2018;9(6):7204–7218.
- Chen GY, Nuñez G. Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol. 2010;10(12):826–837.
- Castiglioni A, Canti V, Rovere-Querini P, et al. High-mobility group box 1 (HMGB1) as a master regulator of innate immunity. Cell Tissue Res. 2011;343(1):189–199.
- De Mori R, Straino S, Di Carlo A, et al. Multiple effects of high mobility group box protein 1 in skeletal muscle regeneration. Arterioscler Thromb Vasc Biol. 2007;27(11):2377–2383.
- Tsung A, Tohme S, Billiar TR. High-mobility group box-1 in sterile inflammation. J Intern Med. 2014;276(5):425–443.
- Henes FO, Chen Y, Bley TA, et al. Correlation of serum level of high mobility group box 1 with the burden of granulomatous inflammation in granulomatosis with polyangiitis (Wegener’s). Ann Rheum Dis. 2011;70(11):1926–1929.
- de Souza AWS, Abdulahad WH, Sosicka P, et al. Are urinary levels of high mobility group box 1 markers of active nephritis in anti-neutrophil cytoplasmic antibody-associated vasculitis? Clin Exp Immunol. 2014;178(2):270–278.
- Headland SE, Norling LV. The resolution of inflammation: principles and challenges. Semin Immunol. 2015;27(3):149–160.
- Libby P, Ridker PM, Hansson GK. Leducq Transatlantic Network on Atherothrombosis. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009;54(23):2129–2138.
- Harrison DG, Guzik TJ, Lob HE, et al. Inflammation, immunity, and hypertension. Hypertension. 2011;57(2):132–140.
- Dawood T, Schlaich MP. Mediators of target organ damage in hypertension: focus on obesity associated factors and inflammation. Minerva Cardioangiol. 2009;57(6):687–704.
- Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care. 2004;27(3):813–823.
- Koyama A, O'Brien J, Weuve J, et al. The role of peripheral inflammatory markers in dementia and Alzheimer's disease: a meta-analysis. J Gerontol A Biol Sci Med Sci. 2013;68(4):433–440.
- Shacter E, Weitzman SA. Chronic inflammation and cancer. Oncol Williston Park. 2002;16:217–226. 229; discussion 230.
- Fogarty AW, Jones S, Britton JR, et al. Systemic inflammation and decline in lung function in a general population: a prospective study. Thorax. 2007;62(6):515–520.
- Joppa P, Petrasova D, Stancak B, et al. Systemic inflammation in patients with COPD and pulmonary hypertension. Chest. 2006;130(2):326–333.
- Medzhitov R. Origin and physiological roles of inflammation. Nature. 2008;454(7203):428–435.
- Speer CP. Inflammation and bronchopulmonary dysplasia: a continuing story. Semin Fetal Neonatal Med. 2006;11(5):354–362.
- Kramer BW. Antenatal inflammation and lung injury: prenatal origin of neonatal disease. J Perinatol. 2008;28(S1):S21–S27.
- Nadeau-Vallée M, Obari D, Palacios J, et al. Sterile inflammation and pregnancy complications: a review. Reproduction. 2016;152(6):R277–R292.
- Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science. 1999;285(5425):248–251.
- Nakamura T, Yamada S, Yoshioka T. Measurement of plasma concentration of high mobility group box1 (HMGB1) in early neonates and evaluation of its usefulness. Clin Chim Acta. 2012;413(1-2):237–239.
- Fukami A, Adachi H, Yamagishi S, et al. Factors associated with serum high mobility group box 1 (HMGB1) levels in a general population. Metabolism. 2009;58(12):1688–1693.